Modification of alternative splicing pathways as a potential approach to chemotherapy.

Many cancer-associated genes are alternatively spliced; their expression leads to the production of multiple splice variants. Although the functions of most of these variants are not well-defined, some have antagonistic activities related to regulated cell death mechanisms. In a number of cancers and cancer cell lines, the ratio of the splice variants is frequently shifted so that the anti-apoptotic splice variant predominates. This observation suggests that modification of splicing, which restores the proper ratio of alternatively spliced gene products, may reverse the malignant phenotype of the cells and offer a gene-specific form of anticancer chemotherapy. Our laboratory has extensively investigated the use of antisense oligonucleotides for shifting the splicing patterns of several genes. Potential application of this method for treatment of cancers, as well as of certain genetic disorders, is discussed.

[1]  R. DiPaola,et al.  Overcoming bcl-2- and p53-mediated resistance in prostate cancer. , 1999, Seminars in oncology.

[2]  Wei-Wei Zhang.  Development and application of adenoviral vectors for gene therapy of cancer , 1999, Cancer Gene Therapy.

[3]  Tumor suppressor genes and breast cancer. , 1999 .

[4]  E. Devilard,et al.  BCL-X and the apoptotic machinery of lymphoma cells. , 1998, Leukemia & lymphoma.

[5]  H. Harn,et al.  Molecular studies into the role of CD44 variants in metastasis in gastric cancer. , 1999, Molecular pathology : MP.

[6]  S. Agrawal,et al.  Repair of thalassemic human beta-globin mRNA in mammalian cells by antisense oligonucleotides. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[7]  P. Herrlich,et al.  CD44 splice variants confer metastatic behavior in rats: homologous sequences are expressed in human tumor cell lines. , 1991, Cancer research.

[8]  C. Prives,et al.  p53: puzzle and paradigm. , 1996, Genes & development.

[9]  C. Thompson,et al.  Bcl-x Antagonizes the Protective Effects of Bcl-x(*) , 1996, The Journal of Biological Chemistry.

[10]  R. Kole.  Modification of pre-mRNA splicing by antisense oligonucleotides. , 1997, Acta biochimica Polonica.

[11]  Manfred Dietel,et al.  Involvement of the c‐erbB‐2 oncogene product in the egf‐induced cell motility of sk‐ov‐3 ovarian cancer cells , 1999 .

[12]  Bonnie F. Sloane,et al.  Cathepsin B: multiple enzyme forms from a single gene and their relation to cancer. , 1996, Enzyme & protein.

[13]  N. M. Hollingsworth,et al.  Red1p, a MEK1-dependent Phosphoprotein That Physically Interacts with Hop1p during Meiosis in Yeast* , 1999, The Journal of Biological Chemistry.

[14]  R. Kole,et al.  Antisense oligonucleotides and RNAs as modulators of pre-mRNA splicing. , 2000, Methods in enzymology.

[15]  D. Mangham,et al.  The normal structure and function of CD44 and its role in neoplasia. , 1998, Molecular pathology : MP.

[16]  A. Lamond,et al.  WT1 interacts with the splicing factor U2AF65 in an isoform-dependent manner and can be incorporated into spliceosomes. , 1998, Genes & development.

[17]  S Jothy,et al.  Adhesion proteins in the biology of breast cancer: contribution of CD44. , 1999, Experimental and molecular pathology.

[18]  A. Krieg,et al.  Applied antisense oligonucleotide technology , 1998 .

[19]  Martin Hofmann,et al.  A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells , 1991, Cell.

[20]  S Weijzen,et al.  Modulation of the immune response and tumor growth by activated Ras , 1999, Leukemia.

[21]  R. Kole,et al.  A common human beta globin splicing mutation modeled in mice. , 1998, Blood.

[22]  P. Brousset,et al.  In vivo patterns of Bcl‐2 family protein expression in breast carcinomas in relation to apoptosis , 1999, The Journal of pathology.

[23]  Jane Y. Wu,et al.  Alternative splicing and programmed cell death. , 1999, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[24]  Y. Tsujimoto,et al.  Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[25]  W. Lee,et al.  Soluble CD44 isoforms in serum as potential markers of metastatic gastric carcinoma. , 1996, Journal of clinical gastroenterology.

[26]  S. Cory,et al.  The Bcl-2 protein family: arbiters of cell survival. , 1998, Science.

[27]  P. Fumoleau,et al.  Genetic alterations in early‐onset invasive breast carcinomas: Correlation of c‐erbB‐2 amplification detected by fluorescence In situ hybridization with p53 accumulation and tumor phenotype , 1999, International journal of cancer.

[28]  M. Knowles,et al.  Correction of Aberrant Splicing of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Gene by Antisense Oligonucleotides* , 1999, The Journal of Biological Chemistry.

[29]  B. Olsen,et al.  Mapping of the human BAX gene to chromosome 19q13.3-q13.4 and isolation of a novel alternatively spliced transcript, BAX delta. , 1995, Genomics.

[30]  K. Pritchard-Jones,et al.  The Wilms tumour gene, WT1, in normal and abnormal nephrogenesis , 1999, Pediatric Nephrology.

[31]  M. Kikuchi,et al.  Low rate of apoptosis and overexpression of bcl‐2 in Epstein–Barr virus‐associated gastric carcinoma , 1999, Histopathology.

[32]  T. Ito,et al.  Decreased expression of Bax is correlated with poor prognosis in oral and oropharyngeal carcinoma. , 1999, Cancer letters.

[33]  W. Kaelin.  The emerging p53 gene family. , 1999, Journal of the National Cancer Institute.

[34]  M. Ladomery,et al.  Multiple roles for the Wilms' tumor suppressor, WT1. , 1999, Cancer research.

[35]  S. Korsmeyer,et al.  Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death , 1993, Cell.

[36]  A. Strasser,et al.  Bim: a novel member of the Bcl‐2 family that promotes apoptosis , 1998, The EMBO journal.

[37]  I. Cascino,et al.  Fas splicing variants and their effect on apoptosis. , 1996, Advances in experimental medicine and biology.

[38]  M. Fujimura,et al.  Up-regulation of ICH-1l protein by thromboxane A2 antagonists enhances cisplatin-induced apoptosis in non-small-cell lung-cancer cell lines , 1999, Journal of Cancer Research and Clinical Oncology.

[39]  I. Bièche,et al.  Increased level of exon 12 alternatively spliced BRCA2 transcripts in tumor breast tissue compared with normal tissue. , 1999, Cancer research.

[40]  M. Mandal,et al.  Overexpression of HER2 modulates bcl-2, bcl-XL, and tamoxifen-induced apoptosis in human MCF-7 breast cancer cells. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[41]  J. Hall,et al.  Transactivation of the WT1 antisense promoter is unique to the WT1[+/−] isoform , 1999, FEBS letters.

[42]  S. Agrawal,et al.  Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides , 1999, Neuromuscular Disorders.

[43]  M. Clarke,et al.  Overexpression of Bcl-XS sensitizes MCF-7 cells to chemotherapy-induced apoptosis. , 1995, Cancer research.

[44]  P. Herrlich,et al.  Activated human lymphocytes and aggressive non-Hodgkin's lymphomas express a homologue of the rat metastasis-associated variant of CD44 , 1993, The Journal of experimental medicine.

[45]  A. Jochemsen,et al.  The Wilms' tumor 1 gene: oncogene or tumor suppressor gene? , 1998, International review of cytology.

[46]  S. Demo,et al.  A Novel Splice Variant of the Cell Death-promoting Protein BAX* , 1998, The Journal of Biological Chemistry.

[47]  C. Thompson,et al.  bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death , 1993, Cell.

[48]  W. G. Zhang,et al.  Antisense Bcl‐2 Retrovirus Vector Increases the Sensitivity of a Human Gastric Adenocarcinoma Cell Line to Photodynamic Therapy , 1999, Photochemistry and photobiology.